» Articles » PMID: 32133362

Multidisciplinary Approach in the Early Detection of Undiagnosed Connective Tissue Diseases in Patients With Interstitial Lung Disease: A Retrospective Cohort Study

Abstract

Interstitial lung disease (ILD) encompasses a wide range of parenchymal lung pathologies with different clinical, histological, radiological, and serological features. Follow-up, treatment, and prognosis are strongly influenced by the underlying pathogenesis. Considering that an ILD may complicate the course of any connective tissue disease (CTD) and that CTD's signs are not always easily identifiable, it could be useful to screen every ILD patient for a possible CTD. The recent definition of interstitial pneumonia with autoimmune features is a further confirmation of the close relationship between CTD and ILD. In this context, the multidisciplinary approach is assuming a growing and accepted role in the correct diagnosis and follow-up, to as early as possible define the best therapeutic strategy. However, despite clinical advantages, until now, the pathways of the multidisciplinary approach in ILD patients are largely heterogeneous across different centers and the best strategy to apply is still to be established and validated. Aims of this article are to describe the organization of our multidisciplinary group for ILD, which is mainly focused on the early identification and management of CTD in patients with ILD and to show our results in a 1 year period of observation. We found that 15% of patients referred for ILD had an underlying CTD, 33% had interstitial pneumonia with autoimmune feature, and 52% had ILD without detectable CTD. Furthermore, we demonstrated that the adoption of a standardized strategy consisting of a screening questionnaire, specific laboratory tests, and nailfold videocapillaroscopy in all incident ILD proved useful in making the right diagnosis.

Citing Articles

A Practical Multidisciplinary Approach to Identifying Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases: A Clinician's Narrative Review.

Biciusca V, Rosu A, Stan S, Cioboata R, Biciusca T, Balteanu M Diagnostics (Basel). 2024; 14(23).

PMID: 39682582 PMC: 11639850. DOI: 10.3390/diagnostics14232674.


Multidisciplinary teams in the clinical care of fibrotic interstitial lung disease: current perspectives.

Cottin V, Martinez F, Smith V, Walsh S Eur Respir Rev. 2024; 31(165).

PMID: 38743511 PMC: 9724802. DOI: 10.1183/16000617.0003-2022.


The Genetic Basis, Lung Involvement, and Therapeutic Options in Niemann-Pick Disease: A Comprehensive Review.

Tirelli C, Rondinone O, Italia M, Mira S, Belmonte L, De Grassi M Biomolecules. 2024; 14(2).

PMID: 38397448 PMC: 10886890. DOI: 10.3390/biom14020211.


The Pattern and Progression of "Usual" Interstitial Pneumonia with Autoimmune Features: Comparison with Patients with Classic Interstitial Pneumonia with Autoimmune Features and Idiopathic Pulmonary Fibrosis.

Libra A, Colaci M, Spicuzza L, Luca G, Fischetti S, Pashalidis G J Clin Med. 2024; 13(2).

PMID: 38256503 PMC: 10816405. DOI: 10.3390/jcm13020369.


Nailfold capillaroscopy findings of interstitial pneumonia with autoimmune features.

Lee S, Min H, Kim S, Kim Y, Yoo K, Kim H Korean J Intern Med. 2023; 38(6):903-911.

PMID: 37488834 PMC: 10636555. DOI: 10.3904/kjim.2022.358.


References
1.
Osawa T, Morimoto K, Sasaki Y, Matsuda S, Yamana K, Yano R . The Serum Ferritin Level Is Associated with the Treatment Responsivity for Rapidly Progressive Interstitial Lung Disease with Amyopathic Dermatomyositis, Irrespective of the Anti-MDA5 Antibody Level. Intern Med. 2017; 57(3):387-391. PMC: 5827321. DOI: 10.2169/internalmedicine.8335-16. View

2.
Sverzellati N, Odone A, Silva M, Polverosi R, Florio C, Cardinale L . Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist. Radiol Med. 2017; 123(4):245-253. PMC: 5849634. DOI: 10.1007/s11547-017-0835-6. View

3.
Bauhammer J, Blank N, Max R, Lorenz H, Wagner U, Krause D . Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response. J Rheumatol. 2016; 43(8):1566-74. DOI: 10.3899/jrheum.150844. View

4.
Alpini C, Lotzniker M, Valaperta S, Bottone M, Malatesta M, Montanelli A . Characterization for anti-cytoplasmic antibodies specificity by morphological and molecular techniques. Auto Immun Highlights. 2015; 3(2):79-85. PMC: 4389067. DOI: 10.1007/s13317-012-0033-4. View

5.
Aggarwal R, Dhillon N, Fertig N, Koontz D, Qi Z, Oddis C . A Negative Antinuclear Antibody Does Not Indicate Autoantibody Negativity in Myositis: Role of Anticytoplasmic Antibody as a Screening Test for Antisynthetase Syndrome. J Rheumatol. 2016; 44(2):223-229. DOI: 10.3899/jrheum.160618. View